(Q37077627)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

main subject

gram-positive bacteria

0 references

author

Philippe Lagacé-Wiens

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1

George G Zhanel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

8

James A Karlowsky

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Shannon Trapp

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Alfred S Gin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Mel DeCorby

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Ethan Rubinstein

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Daryl J Hoban

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

1 reference

1 February 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anti-infective Therapy

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

67-81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

Novel antibacterial agents for skin and skin structure infections

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Dalbavancin: a novel lipoglycopeptide antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Antipneumococcal activity of dalbavancin compared to other agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Treatment options for multidrug-resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Novel antibacterial agents for the treatment of serious Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Clinical pharmacokinetics of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Telavancin: a new lipoglycopeptide with multiple mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Dalbavancin: a novel antimicrobial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Tissue penetration of telavancin after intravenous administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Review of dalbavancin, a novel semisynthetic lipoglycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Origin, structure, and activity in vitro and in vivo of dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Telavancin: a novel lipoglycopeptide for serious gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Dalbavancin: a new option for the treatment of gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

The antimicrobial armamentarium: evaluating current and future treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Glycopeptide antibiotics: from conventional molecules to new derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Glycopeptides: Update on an old successful antibiotic class

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Approaches to vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

In vivo pharmacodynamic activity of the glycopeptide dalbavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Investigational treatments for postoperative surgical site infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Investigational new drugs for the treatment of resistant pneumococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Pharmacokinetics and excretion of dalbavancin in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Effect of dalbavancin on the normal intestinal microflora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Telavancin: in vitro activity against staphylococci in a biofilm model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Ototoxicity: understanding oxidative mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Newer treatment options for skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

Dalbavancin: an investigational glycopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.1.67

21 January 2018

Identifiers

DOI

10.1586/14787210.6.1.67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18251665%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference